Sagimet Biosciences Raises $80M in Crossover Financing

13 Feb, 2021

Sagimet Biosciences Raises $80M in Crossover Financing
Photo by Macau Photo Agency on Unsplash

– Sagimet Biosciences, a San Mateo, Calif.-based clinical-stage biotechnology company, raised $80m in crossover financing.
– The round was led by an undisclosed public equity healthcare investment fund with participation from existing investors (including Ascletis, Kleiner Perkins, New Enterprise Associates (NEA) and Rock Springs Capital) along with new investors (Altium Capital, HM Capital, Invus and PFM Health Sciences).
– The company intends to use the funds to advance its lead program, TVB-2640 for NASH, to explore additional indications, to file an IND on a second FASN inhibitor, TVB-3567, by the end of 2021.

Biopharma Biotechnology North America Therapeutics
Crunchbase icon

Content report

The following text will be sent to our editors: